Crystal Structure of the Sigma-2 Receptor Complexed with Investigational Drug Zervimesine (CT1812)
Gary C. Look, Dominic Gilzer, Franziska Preuß et al. · ACS Medicinal Chemistry Letters · 2026
The investigational drug zervimesine (CT1812) is an allosteric small molecule modulator of the sigma-2 receptor (S2R), known as transmembrane protein 97 (TMEM97), currently in clinical development for Alzheimer's disease and dementia with Lewy bodies. In Phase 2 trials, consistent favorable trends across outcome measures were observed for Alzheimer's disease (NCT03507790), dementia with Lewy Bodies (NCT05225415), and another indication, dry AMD (NCT05893537). The crystal structure of S2R complexed with zervimesine to 2.74 Å resolution reveals this investigational therapeutic bound in the binding site of S2R analogous to that seen previously with other S2R ligands, and is consistent with binding affinity data from a S2R competition assay. The structural interactions by which zervimesine binds with S2R are illuminated, which may shed light on the potential structure-function relationship underlying the favorable effects of zervimesine seen preclinically and clinically, and may foster the design of future S2R modulators for neurodegenerative conditions.
Cited by 0 works. doi:10.1021/acsmedchemlett.6c00215
Authors
- Gary C. Look
- Dominic Gilzer
- Franziska Preuß
- J. Wollenhaupt
- Julius Nitsche
- Jérôme Amaudrut
- Savina Malancona
- Christian Montalbetti
- Anthony O. Caggiano
- Mary E. Hamby
References
- Refinement of Macromolecular Structures by the Maximum-Likelihood Method
- Features and development of Coot
- Highly accurate protein structure prediction with AlphaFold
- XDS
- How good are my data and what is the resolution?
- Pushing the boundaries of molecular replacement with maximum likelihood
- Data processing and analysis with the autoPROC toolbox
- Medicinal chemical properties of successful central nervous system drugs
- UniProt: the Universal Protein Knowledgebase in 2025
- Crystallizing membrane proteins using lipidic mesophases